Cancer survival rates are improving, with 7 in 10 patients now surviving five years or more after diagnosis, according to a recent American Cancer Society report. This is a significant increase from the 1970s, when only about 50% of cancer patients survived five years. The report highlights the dramatic improvements in survival rates for certain cancers, such as liver cancer (7% to 22%), myeloma (32% to 62%), and lung cancer (15% to 28%). These gains are attributed to the development of targeted therapies, which are designed to treat specific gene mutations in tumors. For example, Jane Schlossman, a 61-year-old former marketing professional, was diagnosed with stage 4 adenocarcinoma of the lung, but her survival is attributed to a combination of factors, including a healthy lifestyle, a positive attitude, and targeted therapies based on her EGFR gene mutation. The report emphasizes the importance of continued funding for research and clinical trials, as well as the use of precision medicine, which involves profiling tumors to determine the best treatments. This approach has led to a 'stunning victory' in cancer treatment, turning many cancers from a death sentence into a chronic disease. However, the report also highlights concerning trends, such as the rise in incidence of colorectal cancer in younger people and disparities in prostate cancer death rates among Black men. To sustain progress, support for cancer research and public awareness of risk factors are crucial.
